Drug monitoring in child and adolescent psychiatry for improved efficacy and safety of psychopharmacotherapy

Child and Adolescent Psychiatry and Mental Health

Volumn 3, Issue , 2009, Pages

  Mehler Wex, Claudia ^a   Kölch, Michael ^a   Kirchheiner, Julia ^a   Antony, Gisela ^b   Fegert, Jörg M ^a   Gerlach, Manfred ^c  

^a UNIVERSITY OF ULM   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CLOMIPRAMINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; IMIPRAMINE; LITHIUM; NORTRIPTYLINE; OLANZAPINE; PSYCHOTROPIC AGENT;

ARTICLE; CHILD PSYCHIATRY; DATA BASE; DEPRESSION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; GENETIC VARIABILITY; HEALTH CARE SYSTEM; HUMAN; INTERNET; MENTAL DISEASE; MENTAL PATIENT; OFF LABEL DRUG USE; PHARMACODYNAMICS; PHARMACOGENETICS; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA;

EID: 65549130988     PISSN: None     EISSN: 17532000     Source Type: Journal    
DOI: 10.1186/1753-2000-3-14     Document Type: Article

References (44)

1. Competence Network on TDM in Child and Adolescent Psychiatry http://tdm-kjp.de
2. Zito JM Tobi H Berg LTWdJ-vd Fegert JM Safer DJ Janhsen K Hansen DG Gardner JF Glaeske G Antidepressant prevalence for youths: A multi-national comparison Pharmacoepidemiology and Drug Safety 2006, 15(11):793-798 10.1002/pds.1254
3. Fegert JM Kölch M Zito JM Glaseke G Jahnsen Antidepressant Use in children and Adolescents in Germany Jorunal of Child and Adolescent Psychopharmacology 2006, 16(1/2):197-206 10.1089/cap.2006.16.197
4. Zito JM Safer DJ Berg LTdJ-vd Janhsen K Fegert JM Gardner JF Glaeske G Valluri SC A three-country comparison of psychotropic medication prevalence in youth. (2008b) Child and Adolescent Psychiatry and Mental Health 2008, 2:26 10.1186/1753-2000-2-26
5. Conroy S Choonara I Impicciatore P Mohn A Arnell H Rane A Knoeppel C Seyberth H Pandolfini C Raffaelli MP et al Survey of unlicensed and off label drug use in paediatric wards in European countries Britisch Medical Journal 2000, 320(7227);79-82 10.1136/bmj.320.7227.79
6. Knöppel C Klinger O Soergel M Seyberth H Leonhardt A Anwendung von Medikamenten außerhalb der Zulassung oder ohne Zulassung bei Kindern Monatschr Kinderheilkd 2000, 148:904-908 10.1007/s001120050670
7. Bücheler R Schwab M Mörike K Kalchthaler B Mohr H Schröder H Schwoerer P Gleiter C Off-label prescribing to outpatient children British Medical Journal 2002, 324:1311-1312 113768 12039825 10.1136/bmj.324.7349.1311
8. Zito JM Derivan AT Kratochvil CJ Safer DJ Fegert JM Greenhill L Off-label psychopharmacologic prescribing for children: History supports close clinical monitoring. (2008a) Child and Adolescent Psychiatry and Mental Health 2008, 2:24 10.1186/1753-2000-2-24
9. Kölch M Schnoor K Fegert JM Ethical issues in psychopharmacology of children and adolescents Current Opinion Psychiatry 2008, 21(6):598-605 10.1097/YCO.0b013e328314b776
10. Entorf H Fegert JM Kölch M Children in Need of Medical Innovation ZEW Zentrum für Europäische Wirtschaftsforschung GmbH 2004
11. Vitiello B Heiligenstein JH Riddle MA Greenhill LL Fegert JM The Interface Between Publicly Funded and Industry-Funded Research in Pediatric Psychopharmacology: Opportunities for Integration and Collaboration BIOL PSYCHIATRY 2004, 56:3-9 10.1016/ j.biopsych.2004.03.011 15219466
12. Whittington C Kendall T Fonagy P Cotrell D Cotgrove A Boddinton E Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data Lancet 2004, 363:1341-1345 10.1016/S0140-6736(04)16043-1 15110490
13. Safer DJ Zito JM Treatment-Emergent Adverse Events from Selective Serotonin Reuptake Inhibitors by Age Group: Children versus Adolescents Journal of Child and Adolescent Psychopharmacology 2006, 16(1/2):159-169 10.1089/cap.2006.16.159
14. Goodyer I Dubicka B Wilkinson P Kelvin R Roberts C Byford S Breen S Ford C Barrett B Leech A et al Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: Randomised controlled trial British Medical Journal 2007, 335:142 1925185 17556431 10.1136/ bmj.39224.494340.55
15. Meyer T Kossmann-Böhm S Schlottke P Do child psychiatrists in Germany diagnose bipolar disorders in children and adolescents? Results from a survey Bipolar Disord 2004, 6(5):426-431 10.1111/ j.1399-5618.2004.00131.x 15383136
16. Soutullo C Chang K Díez-Suárez A Figueroa-Quintana A Escamilla-Canales I Rapado-Castro M Ortuño F Bipolar disorder in children and adolescents: International perspective on epidemiology and phenomenology Bipolar Disord 2005, 7(6):497-506 10.1111/ j.1399-5618.2005.00262.x 16403175
17. Bodenheimer T Uneasy alliance - clinical investigators and the pharmaceutical industry N Engl J Med 2000, 342(20):1539-1544 10.1056/ NEJM200005183422024 10816196
18. McCracken JT McGough J Shah B Cronin P Hong D Aman MG Arnold LE Lindsay R Nash P Hollway J et al Risperidone in Children with Autism and Serious Behavioral Problems The New England Journal of Medicine 2002, 347:314-321 10.1056/NEJMoa013171 12151468
19. Schubert S Lippert H-D Fegert JM Kölch M Industrieunabhängige Forschung an Kindern und die 12. Novelle des Arzneimittelgesetzes Monatsschrift Kinderheilkunde 2007, 155(2):152-156 10.1007/ s00112-006-1458-5
20. Kölch M Schnoor K Fegert J The EU-regulation on medicinal products for paediatric use. Impacts on child and adolescent psychiatry and clinical research with minors European Child and Adolescent Psychiatry 2007, 16(4):229-235 10.1007/s00787-006-0594-8
21. Kearns G Abdel-Rahman S Alander S Blowey D Leeder J Kauffman R Developmental pharmacology - Drug disposition, action, and therapy in infants and children New England Journal of Medicine 2003, 349(12):1157-1167 10.1056/NEJMra035092 13679531
22. Findling RL McNamara NK Stansbrey RJ Feeny NC Young CM Peric FV Youngstrom EA The Relevance of Pharmacokinetic Studies in Designing Efficacy Trials in Juvenile Major Depression Journal of Child and Adolescent Psychopharmacology 2006, 16(1-2):131-145 10.1089/ cap.2006.16.131
23. Giedd N Blumenthal J Jeffries NO Castellanos FX Liu H Zijdenbos A Paus Tc Evans AC Rapoport JL Brain development during childhood and adolescence: A longitudinal MRI study Nature Neuroscience 1999, 2:861-863 10.1038/13158 10491603
24. Seeman P Bzowej NH Guan H-C Bergeron C Becker LE Reynolds GP Bird ED Riederer P Jellinger K Watanabe S et al Human brain dopamine receptors in children and aging adults Synapse 1987, 1(5):399-404 10.1002/ syn.890010503 3505371
25. Federow H Tribl F Halliday G Gerlach M Riederer P K D Neuromelanin in human dopamine neurons: Comparison with pheripheral melanins and relevance to Parkinson's disease Progr Neurobiol 2005, 75:109-124 10.1016/j.pneurobio.2005.02.001
26. Gerlach M Hühnerkopf R Rothenhöfer S Libal G Burger R Clement HW Fegert JM Wewetzer C Mehler-Wex C Therapeutic Drug Monitoring of Quetiapine in Adolescents with Psychotic Disorders Pharmacopsychiatry 2007, 40:72-76 10.1055/s-2007-972573 17447177
27. Evans W McLeod H Pharmacogenomics - drug disposition, drug targets, and side effects The New England Journal of Medicine 2003, 348(6):538-549 10.1056/NEJMra020526 12571262
28. Evans W Relling M Pharmacogenomics: Translating functional genomics into rational therapeutics Science 1999, 286(5439):487-491 10.1126/ science.286.5439.487 10521338
29. Kirchheiner J CYP2D6 Phenotype Prediction From Genotype: Which System Is the Best? Clinical Pharmacology & Therapeutics 2008, 83(2):225-227 10.1038/sj.clpt.6100455
30. Laine K Tybring G Hartter S Andersson K Svensson J Widen J Bertilsson L Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test Clin Pharmacol Ther 2001, 70(4):327-335 11673748
31. Bertilsson L Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19 Clin Pharmacokinet 1995, 29(3):192-209 10.2165/ 00003088-199529030-00005 8521680
32. Akullu E Persson I Bertilsson L Johansson I Rodrigues F Ingelman-Sundberg M Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles J Pharmacol Exp Ther 1996, 278(1):441-446 8764380
33. Wedlund P The CYP2C19 enzyme polymorphism Pharmacology 2000, 61(3):174-183 10.1159/000028398 10971203
34. Koren G Cairns J Chitayat D Gaedigk A Leeder S Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother The Lancet 2006, 368:704-705 10.1016/S0140-6736(06)69255-6
35. Kirchheiner J Brockmoller J Clinical consequences of cytochrome P450 2C9 polymorphisms Clin Pharmacol Ther 2005, 77(1):1-16 10.1016/ j.clpt.2004.08.009 15637526
36. Kirchheiner J Brøsen K Dahl ML Gram LF Kasper S Roots I Sjoqvist F Spina E Brockmöller J CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: A first step towards subpopulation-specific dosages Acta Psychiatr Scand 2001, 104(3):173-192 10.1034/j.1600-0447.2001.00299.x 11531654
37. McLeod HL Siva C The thiopurine S-methyltransferase gene locus - implications for clinical pharmacogenomics Pharmacogenomics 2002, 3(1):89-98 10.1517/14622416.3.1.89 11966406
38. Baumann P Hiemke C Ulrich S Eckermann G Gaertner I Gerlach M Kuss H Laux G Müller-Oerlinghausen B Rao M et al The AGNP-TDM expert group consensus guidelines: Therapeutic drug monitoring in Psychiatry Pharmacopsychiatry 2004, 37:243-265 10.1055/s-2004-832687 15551191
39. Oberlander T Bonaguro R Misri S Papsdorf M Ross C Simpson E Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications Mol Psychiatry 2008, 13(1):65-73 10.1038/ sj.mp.4002007 17519929
40. Expert group of the Society of Neuropsychopharmacology and Pharmacopsychiatry (AGNP) http://www.agnp.de
41. Laux G Riederer P Plasmaspiegelbestimmungen von Psychopharmaka Therapeutisches Drug-Monitoring Versuch einer Standortbestimmung Stuttgart: Wissenschaftliche Verlagsgesellschaft 1992
42. Hiemke C Härtter S H W Therapeutisches Drug Monitoring (TDM) Laboruntersuchungen in der psychiatrischen Routin Stuttgart: Thieme Gastpar M, Banger M 2000, 106-133
43. Gerlach M Rothenhöfer S Mehler-Wex C Fegert JM Schulz E Wewetzer C Warnke A Therapeutisches Drug-Monitoring in der Kinder- und Jugendpsychiatrie - Grundlagen und praktische Empfehlungen Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie 2006, 34(1):5-13 10.1024/1422-4917.34.1.5
44. Child and Adolescent Psychiatry Trials Network http://www.captn.org